GlassScriptPhysician profile
Hanane Chaibainou
NPI 1316241565
$16,178.18
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $121 · 2023: $330 · 2024: $1,671 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $5,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,667.93 |
| Food and Beverage | $5,050.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insightec,INC | $10,888.71 | 2021-2025 | Exablate |
| Abbvie INC. | $1,352.34 | 2023-2025 | |
| Ucb, INC. | $680.28 | 2024-2025 | Fintepla, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $482.44 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lundbeck LLC | $302.49 | 2024-2025 | Vyepti, Rexulti |
| Pfizer INC. | $296.66 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.98 | 2024-2025 | Zeposia |
| Medtronic, INC. | $213.59 | 2021-2022 | |
| Axsome Therapeutics, INC. | $201.10 | 2025 | Symbravo |
| Lilly USA, LLC | $188.84 | 2024-2025 | Kisunla, Emgality, Amyvid |
| Biogen, INC. | $172.91 | 2023-2025 | Vumerity, Tysabri, Leqembi |
| Neurocrine Biosciences, INC. | $162.98 | 2024-2025 | Ingrezza |
| Eisai INC. | $161.33 | 2023-2025 | |
| Celgene Corporation | $151.60 | 2024-2025 | Zeposia |
| Scilex Pharmaceuticals INC. | $127.91 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $109.80 | 2022-2025 | General - Dbs |
| Argenx US, INC. | $71.79 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Grifols USA, LLC | $55.14 | 2024-2025 | Gamunex-C |
| Mdd US Operations, LLC | $38.07 | 2025 | Gocovri |
| Vanda Pharmaceuticals INC. | $37.72 | 2024 | Ponvory |
| Amneal Pharmaceuticals LLC | $37.15 | 2025 | Crexont |
| Ani Pharmaceuticals, INC. | $23.62 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $21.36 | 2025 | Inbrija |
| Springworks Therapeutics, INC. | $20.16 | 2025 | Gomekli |
| Alexion Pharmaceuticals, INC. | $18.61 | 2024 | Ultomiris |
| Impel Pharmaceuticals LLC | $18.03 | 2025 | Trudhesa |
| Harmony Biosciences LLC | $16.80 | 2025 | |
| Sk Life Science, INC. | $16.67 | 2024 | |
| Amgen INC. | $15.86 | 2024 | Aimovig |
| Aucta Pharmaceuticals, INC. | $15.75 | 2024 | Motpoly Xr |
| Jazz Pharmaceuticals INC. | $14.95 | 2024 | |
| Acadia Pharmaceuticals INC | $13.54 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hanane Chaibainou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.